Medical technology company Hemanext is partnering with the Silicon Valley-based nonprofit Sickle Cell 101 (SC101) to promote…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases…
To improve life for people with sickle cell disease (SCD), Global Blood Therapeutics (GBT) has awarded grants worth $50,000…
To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes…
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual…
From sporting red gear to entering a spoken word contest, supporters globally are poised to mark World Sickle Cell…
Two U.S. nonprofits are partnering to tackle legislative issues that benefit sickle cell disease (SCD) patients and their families.
To inform sickle cell disease (SCD) patients and their caregivers about blood transfusions, which are commonly used to treat…
Registration is open for the 8th annual “Walk with the Stars,” one of the largest fundraisers organized by the…
Rare Disease Day at NIH, organized by the National Institutes of Health (NIH) and taking place on March 1,…